<DOC>
	<DOCNO>NCT01032148</DOCNO>
	<brief_summary>The purpose study find effect drug call LBH589 give people recurrent refractory Hodgkin Non-Hodgkin 's lymphoma . The safety drug also study . The participant ' physical state , change size tumor , state Hodgkin non-Hodgkin 's Lymphoma , laboratory finding take on-study help researcher decide LBH589 safe effective .</brief_summary>
	<brief_title>Study LBH589 , A Deacetylase Inhibitor Patients With Recurrent Refractory Hodgkin Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This open-label , standard 3-3 dose find scheme modification allow intra-patient dose modification determine maximum tolerate dose toxicity profile LBH589 patient recurrent refractory Hodgkin 's non-Hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Male female patient age ≥ 18 year old relapsed/refractory Hodgkin lymphoma NHL patient relapse refractory receive minimum two prior therapy Ability provide write informed consent obtain prior participation study relate procedure perform Laboratory requirement : ANC ≥ 1.5 x 10 ( 9th ) /L , unless due bone marrow involvement lymphoma Hemoglobin ≥ 9 g/dl without pack red blood cell dependency , unless due bone marrow involvement lymphoma Platelets ≥ 100 x 10 ( 9th ) /L , unless due bone marrow involvement lymphoma Serum creatinine ≤ 1.5 x Upper limit Normal , calculate Creatinine Clearance ≥ 50 mL/min AST ALT ≤ 2.5 x Upper limit Normal , unless due liver involvement lymphoma Serum bilirubin ≤ 1.5 x Upper limit Normal Albumin &gt; 3.0 g/dl Serum potassium ≥ Lower limit Normal Total serum calcium [ correct serum albumin ] ionize calcium ≥ Lower limit normal Serum magnesium ≥ Lower limit Normal Serum phosphorus ≥ Lower limit Normal TSH ≥ LLN free T4 within normal limit . Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . Baseline MUGA ECHO must demonstrate LVEF ≥ 50 % ECOG Performance Status ≤ 2 Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medication study within 5 day prior first LBH589 treatment Peripheral neuropathy ≥ CTCAE grade 1 Impaired cardiac function clinically significant cardiac disease , include one following : Patients congenital QT syndrome History presence sustain ventricular tachyarrhythmia . Any history ventricular fibrillation torsade de pointes Bradycardia define Heart Rate &lt; 50 bpm . Patients pacemaker eligible Heart Rate ≥ 50 bpm Screening EKG QTc.450msec Right Bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina ≤ 6 month prior start study drug clinically significant heart disease ( e.g . CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension history poor compliance antihypertensive regimen ) Impairment GI function GI disease may significantly alter absorption LBH589 Patients Diarrhea &gt; CTCAE grade 1 Other concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value could cause unaccepted safety risk compromise compliance protocol Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Concomitant use CYP3A4 inhibitor Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( ever longer ) recover side effect therapies Patients receive either immunotherapy within ≤ 8 week ; chemotherapy within ≤ 4 week radiation therapy &gt; 30 % marrowbearing bone within ≤ week prior start study treatment yet recover side effect therapies Patients active bleeding tendency receive treatment therapeutic dos sodium warfarin coumadin derivative . Low dos Coumadin ( e.g.≤2 mg/day ) maintain line patency allow . Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential use effective method birth control Male patient whose sexual partner woman childbearing potential use effective birth control Patients prior malignancy within 5 year ( except basal squamous cell carcinoma , situ cancer cervix early stage prostate bladder carcinoma ) Patients known positivity HIV hepatitis C : baseline test HIV Hepatitis C require Prior allogenic stem cell transplant Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff Patients take CYP2D6 inhibitor carefully monitor , drug necessarily contraindicate use concomitantly LBH . Use drug exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
</DOC>